G
Gordon L. Amidon
Researcher at University of Michigan
Publications - 469
Citations - 38521
Gordon L. Amidon is an academic researcher from University of Michigan. The author has contributed to research in topics: Intestinal absorption & Prodrug. The author has an hindex of 86, co-authored 466 publications receiving 35880 citations. Previous affiliations of Gordon L. Amidon include ETH Zurich & Merck & Co..
Papers
More filters
Journal ArticleDOI
Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group.
Susan M. Abdel-Rahman,Gordon L. Amidon,Ajay Kaul,Ajay Kaul,Viera Lukacova,Alexander A. Vinks,Alexander A. Vinks,Gregory T. Knipp +7 more
TL;DR: For a PBCS to be truly meaningful, it needs to be broken down into several different age groups that account for developmental changes in intestinal permeability, luminal contents, and gastrointestinal (GI) transit.
Journal ArticleDOI
Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Amitriptyline Hydrochloride
Ruben H. Manzo,María Eugenia Olivera,Gordon L. Amidon,Vinod P. Shah,Jennifer B. Dressman,D. M. Barends +5 more
TL;DR: In this article, literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing amitriptyline hydrochloride are reviewed.
Journal ArticleDOI
Utilization of Peptide Carrier System To Improve Intestinal Absorption: Targeting Prolidase as a Prodrug-Converting Enzyme
Jane P. F. Bai,Ming Hu,Ming Hu,Pullachipatti K. Subramanian,Henry I. Mosberg,Gordon L. Amidon +5 more
TL;DR: Results demonstrate that prolidase may serve as a prodrug-converting enzyme for the dipeptide-type prodrugs, utilizing the peptide carrier for transport of pro drugs into the mucosal cells and prolid enzyme, a cytosolic enzyme, to release the drug.
Journal ArticleDOI
Summary Workshop Report: Bioequivalence, Biopharmaceutics Classification System, and Beyond
James E. Polli,Bertil Abrahamsson,Lawrence X. Yu,Gordon L. Amidon,John M. Baldoni,Jack Cook,Paul Fackler,Kerry John Hartauer,Gordon Johnston,Steve L. Krill,Robert A. Lipper,Waseem Malick,Vinod P. Shah,Duxin Sun,Helen Winkle,Yunhui Wu,Hua Zhang +16 more
TL;DR: Key highlights of the workshop were the described granting of over a dozen BCS-based biowaivers by the FDA for Class I drugs whose formulations exhibit rapid dissolution, and continued scientific support for a number of permeability methodologies to assess BCS permeability class.
Journal ArticleDOI
The Low/High BCS Permeability Class Boundary: Physicochemical Comparison of Metoprolol and Labetalol
TL;DR: Neither metoprolol nor labetalol can be regarded as optimal low/high-permeability class boundary standard, and both drugs exhibit significant segmental-dependent permeability along the gastrointestinal tract.